ALK and lung adenocarcinoma: EML4/ALK fusion-positive lung adenocarcinoma was predicted to be borderline more sensitive to Alectinib (p = 0.0632) and EML4/ALK or ROS1 fusion-positive lung adenocarcinoma was predicted to be more sensitive to Crizotinib (p = 0.044).